Delivery of pharmaceutical products for treatment of oncological and hematological diseases and blood coagulation factors for the needs of UMBAL Dr. Georgi Stranski EAD - Pleven
Originaltitel der Bekanntmachung
Bulgaria – Pharmaceutical products – „Доставка на лекарствени продукти за лечение на онкологични и хематологични заболявания и фактори за кръвосъсирване за нуждите на УМБАЛ „Д-р Георги Странски” ЕАД - Плевен”
Opportunity Score
Warum diese Bewertung?
Chance
70 / 100
Komplexität
60 / 100
Risikofaktoren
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Strong opportunityWichtige Fakten
- BGN 324.7M estimated value
- Dynamic Purchasing System (DPS)
- Supplies contract
- 1 lot
- Duration 36 MONTH
- Delivery of pharmaceutical products for oncology and hematology
- Delivery of blood coagulation factors
Vollständige Zusammenfassung anzeigen
This is a restricted procedure for a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products for oncological and hematological diseases and blood coagulation factors to the University Hospital Dr. Georgi Stranski in Pleven, Bulgaria. The estimated value is 324,733,078.61 BGN, with a duration of 36 months. The deadline for submission is 2028-05-02. The award is based on lowest price.
Risiken
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Must be a registered trader permitted to wholesale medicinal products
- Must hold a wholesale authorization for medicinal products from the Bulgarian Drug Agency (IAL) or equivalent from another EU member state
- If manufacturer, must hold production authorization or authorization from the product manufacturer
Anforderungen können unvollständig sein.
Zuschlagskriterien
Lot 1
Auftraggeber
Ort
гр. Плевен, BGR
Auftraggeberprofil
Kennung
114532352
Tätigkeit
Health
Lose (1)
LOT-0001
Delivery of pharmaceutical products for treatment of oncological and hematological diseases and blood coagulation factors for the needs of UMBAL Dr. Georgi Stranski EAD - Pleven
Supply of oncological and hematological medicines and blood clotting factors as per technical specifications. The lot is a DPS with continuous competition.
BGN 324.7M
Geschätzter Wert
Ort
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
На първо място се класира участникът, предложил най-ниска цена. Останалите оферти заемат места в класирането по низходящ ред
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
„Доставка на лекарствени продукти за лечение на онкологични и хематологични заболявания и фактори за кръвосъсирване за нуждите на УМБАЛ „Д-р Георги Странски” ЕАД - Плевен”
Originale TED-Beschreibung
Процедура по реда на Закона за обществените поръчки за лекарствени продукти за лечение на онкологични и хематологични и фактори за кръвосъсирване за нуждите на „УМБАЛ Д-р Георги Странски” ЕАД – Плевен,, по смисъла на Закона за лекарствените продукти в хуманната медицина , съгласно техническата спецификация и условията на настоящата документация.
Vergabedetails
- Veröffentlichungsdatum
- 02 Apr 2025
- Sprachen
- Bulgarian
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 216830-2025
Dokumente (1)
Ähnliche Ausschreibungen
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Warum diese Bewertung?
Chance
70 / 100
Komplexität
60 / 100
Risikofaktoren
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications